BBLG
Bone Biologics Corporation
NASDAQ · Healthcare · Medical - Devices · US
$0.57
+1.70%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.1x
Market Cap
$1.56M
MomentumView details →
1D Return
+1.70%
YTD Return
−61.38%
RSI (14)
24.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.1x
Market Cap
$1.56M
RSI (14)
24.3
MomentumView details →
1D Return
+1.70%
YTD Return
−61.38%
SummaryUpdated Jun 1, 2026
Bone Biologics Corporation (NASDAQ:BBLG) is a clinical-stage medical device company founded in 2004 and headquartered in Burlington, Massachusetts. The company went public in October 2021 and focuses on developing innovative bone regeneration solutions for spinal fusion procedures. Bone Biologics operates as a pre-revenue biotechnology company, dedicating its efforts to advancing a proprietary recombinant protein technology that aims to enhance bone healing outcomes in orthopedic surgery.
Similar companies
Latest newsMore news →
Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months, enhancing manufacturing and distribution flexibility ahead of pivotal-study scale.23d agoBone Biologics Corp signed a $3.0 million at-the-market private placement agreement with an institutional investor, issuing common stock and pre-funded warrants, plus Series F and Series G warrants, with $3.0 million in upfront gross proceeds and up to $6.0 million additional from warrant exercises.58d ago